First gene therapy for a blinding eye disease receives FDA approval
Today we are celebrating the FDA’s pathbreaking approval of Luxturna. We have been following the development of Luxturna closely. Today’s landmark FDA approval makes Luxturna the first gene therapy approved in the…
Research News
June 2023 Pre-Clinical Trial Research Updates for Inherited Retinal Diseases Below are updates from gene-specific pre-clinical studies for inherited retinal diseases that we hope will move into the clinic in the coming…
New Survey Initiative Engages Patients as Experts and Collaborators
Last year Fighting Blindness Canada launched its Vision Care Pathways (VCP) online tool, a set of resources and guides for people living with eye diseases. These diseases include rare genetic disorders such…
The Era of Gene Therapy – A Panel Discussion
In this panel discussion from Vision Quest Vancouver on April 27, 2019, experts from around the world introduced the new era of gene therapy and discussed what this means for the future…
Leber Congenital Amaurosis
Jump to: Symptoms | Diagnosis | Treatments and Care | Clinical Trials | Patient Registry | Research and Health Policy | Resources | References Overview Leber congenital amaurosis (LCA) is a genetic…
X-Linked Retinoschisis
Jump to: Symptoms | Diagnosis | Treatments | Clinical Trials | Patient Registry | Research | Resources | References Overview X-linked retinoschisis (XLRS) is a genetic disorder that causes vision loss and…
Join the Fight!
Learn how your support is helping to bring a future without blindness into focus! Be the first to learn about the latest breakthroughs in vision research and events in your community by subscribing to our e-newsletter that lands in inboxes the beginning of each month.